首页 > 最新文献

Journal of the American Academy of Dermatology最新文献

英文 中文
Differences in NIH Funding, Publications, and H-Index between Men and Women Who Are Endowed Dermatology Chairs.
IF 12.8 1区 医学 Q1 DERMATOLOGY Pub Date : 2025-03-12 DOI: 10.1016/j.jaad.2025.03.013
Ferdos Abdulkader, Sana Khan, Claire Reynolds, Ramiro Rodriguez, Ani Oganesyan, Robert P Dellavalle
{"title":"Differences in NIH Funding, Publications, and H-Index between Men and Women Who Are Endowed Dermatology Chairs.","authors":"Ferdos Abdulkader, Sana Khan, Claire Reynolds, Ramiro Rodriguez, Ani Oganesyan, Robert P Dellavalle","doi":"10.1016/j.jaad.2025.03.013","DOIUrl":"https://doi.org/10.1016/j.jaad.2025.03.013","url":null,"abstract":"","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":""},"PeriodicalIF":12.8,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143630530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Alar Rim Preservation Advancement (ARPA) Flap.
IF 12.8 1区 医学 Q1 DERMATOLOGY Pub Date : 2025-03-11 DOI: 10.1016/j.jaad.2025.03.011
R Maxwell Regester, Brian Sayles, Amy Cannella, Amy Rau, Anthony J Griess
{"title":"Alar Rim Preservation Advancement (ARPA) Flap.","authors":"R Maxwell Regester, Brian Sayles, Amy Cannella, Amy Rau, Anthony J Griess","doi":"10.1016/j.jaad.2025.03.011","DOIUrl":"https://doi.org/10.1016/j.jaad.2025.03.011","url":null,"abstract":"","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":""},"PeriodicalIF":12.8,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143623421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ethics of Ambient Documentation.
IF 12.8 1区 医学 Q1 DERMATOLOGY Pub Date : 2025-03-11 DOI: 10.1016/j.jaad.2025.03.007
Shae Chambers, Ameya Gangal, Benjamin Stoff
{"title":"Ethics of Ambient Documentation.","authors":"Shae Chambers, Ameya Gangal, Benjamin Stoff","doi":"10.1016/j.jaad.2025.03.007","DOIUrl":"https://doi.org/10.1016/j.jaad.2025.03.007","url":null,"abstract":"","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":""},"PeriodicalIF":12.8,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143623433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-term safety and efficacy of delgocitinib cream for up to 52 weeks in adults with Chronic Hand Eczema: results of the phase 3 open-label extension DELTA 3 trial following the DELTA 1 and 2 trials.
IF 12.8 1区 医学 Q1 DERMATOLOGY Pub Date : 2025-03-11 DOI: 10.1016/j.jaad.2025.03.008
Melinda Gooderham, Sonja Molin, Robert Bissonnette, Margitta Worm, Marie-Noëlle Crépy, Luca Stingeni, Richard B Warren, Sibylle Schliemann, Marie-Louise Schuttelaar, Silvia Ferrucci, Esther Serra-Baldrich, Jonathan I Silverberg, Cherry Lou Balita-Crisostomo, Marie Louise Oesterdal, Ursula Plohberger, Tove Agner

Background: There are no topical treatments that have been specifically developed and approved for moderate to severe Chronic Hand Eczema (CHE).

Objective: To evaluate the long-term safety and efficacy of delgocitinib cream 20 mg/g as needed for 36 weeks in adults with CHE.

Methods: In phase 3 open-label DELTA 3 (NCT04949841), patients who completed the 16-week(W) treatment period in DELTA 1 and 2 were treated on an as-needed basis with twice-daily delgocitinib for 36 weeks (n=801). Patients with Investigator's Global Assessment for CHE (IGA-CHE)≥2 received treatment until IGA-CHE≤1 was achieved. Primary endpoint was number of treatment-emergent adverse events (AEs). Key secondary endpoints were IGA-CHE 0/1 and ≥75%/≥90% improvement in Hand Eczema Severity Index (HECSI-75/90) scores.

Results: Delgocitinib was well tolerated (n=801; R=231.1; PYO=535.7), with most frequent AEs being COVID-19 and nasopharyngitis. DELTA 3 baseline IGA-CHE 0/1 (24.6%), HECSI-75/HECSI-90 (51.8%/31.8%) were maintained to W36 (30.0% and 58.6%/36.6%, respectively) among delgocitinib-treated patients in the parent trials. Among those previously treated with cream vehicle, corresponding response rates improved from DELTA 3 baseline (9.1% and 23.7%/12.0%, respectively) to W36 (29.5% and 51.5%/35.7%).

Limitations: Open-label trial.

Conclusion: Delgocitinib cream treatment was well-tolerated and efficacious in maintaining disease control in CHE patients up to 52 weeks.

{"title":"Long-term safety and efficacy of delgocitinib cream for up to 52 weeks in adults with Chronic Hand Eczema: results of the phase 3 open-label extension DELTA 3 trial following the DELTA 1 and 2 trials.","authors":"Melinda Gooderham, Sonja Molin, Robert Bissonnette, Margitta Worm, Marie-Noëlle Crépy, Luca Stingeni, Richard B Warren, Sibylle Schliemann, Marie-Louise Schuttelaar, Silvia Ferrucci, Esther Serra-Baldrich, Jonathan I Silverberg, Cherry Lou Balita-Crisostomo, Marie Louise Oesterdal, Ursula Plohberger, Tove Agner","doi":"10.1016/j.jaad.2025.03.008","DOIUrl":"https://doi.org/10.1016/j.jaad.2025.03.008","url":null,"abstract":"<p><strong>Background: </strong>There are no topical treatments that have been specifically developed and approved for moderate to severe Chronic Hand Eczema (CHE).</p><p><strong>Objective: </strong>To evaluate the long-term safety and efficacy of delgocitinib cream 20 mg/g as needed for 36 weeks in adults with CHE.</p><p><strong>Methods: </strong>In phase 3 open-label DELTA 3 (NCT04949841), patients who completed the 16-week(W) treatment period in DELTA 1 and 2 were treated on an as-needed basis with twice-daily delgocitinib for 36 weeks (n=801). Patients with Investigator's Global Assessment for CHE (IGA-CHE)≥2 received treatment until IGA-CHE≤1 was achieved. Primary endpoint was number of treatment-emergent adverse events (AEs). Key secondary endpoints were IGA-CHE 0/1 and ≥75%/≥90% improvement in Hand Eczema Severity Index (HECSI-75/90) scores.</p><p><strong>Results: </strong>Delgocitinib was well tolerated (n=801; R=231.1; PYO=535.7), with most frequent AEs being COVID-19 and nasopharyngitis. DELTA 3 baseline IGA-CHE 0/1 (24.6%), HECSI-75/HECSI-90 (51.8%/31.8%) were maintained to W36 (30.0% and 58.6%/36.6%, respectively) among delgocitinib-treated patients in the parent trials. Among those previously treated with cream vehicle, corresponding response rates improved from DELTA 3 baseline (9.1% and 23.7%/12.0%, respectively) to W36 (29.5% and 51.5%/35.7%).</p><p><strong>Limitations: </strong>Open-label trial.</p><p><strong>Conclusion: </strong>Delgocitinib cream treatment was well-tolerated and efficacious in maintaining disease control in CHE patients up to 52 weeks.</p>","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":""},"PeriodicalIF":12.8,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143624611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mohs micrographic surgery reduces the risk of reconstruction with positive margins, repeat surgeries, and time to definitive reconstruction compared to conventional excision of hand and foot melanomas: a retrospective cohort study.
IF 12.8 1区 医学 Q1 DERMATOLOGY Pub Date : 2025-03-11 DOI: 10.1016/j.jaad.2025.03.012
Daniela Frankel, Karla Valdes-Morales, Mara D Trifoi, Stephanie K Lin, Annika M Deitermann, Manisha Banala, Esther Zhang, Nicole Easo, Marissa Lubeck, Dylan Haynes, Daniel Lewis, Shannon T Nugent, Jeremy R Etzkorn, Neha N Jariwala, Junqian Zhang, Joanna L Walker, H William Higgins, Joseph F Sobanko, Cerrene N Giordano, Parnaz Daneshpajouhnejad, Mitul Modi, Ines C Lin, Benjamin Chang, Jason Wink, Giorgos Karakousis, John Miura, Christopher J Miller

Background: Hand and foot melanomas (HFM) have increased risk for positive margins after conventional excision (CE). Mohs micrographic surgery (MMS) may improve margin clearance prior to reconstruction. Rates of reconstruction with positive margins have not been compared after CE versus MMS for HFM.

Objective: To compare rates of reconstruction with positive margins after CE or MMS of HFM.

Methods: In situ and invasive melanomas of hands and feet treated with CE or MMS with MART-1 immunostaining between 1994-2023 were identified from an academic center. The primary outcome was rate of reconstruction with positive margins after CE vs MMS. Secondary outcomes were repeat excision and time to definitive reconstruction after CE vs MMS.

Results: Of 269 HFM, 180 (66.91%) were treated with MMS versus 89 (33.09%) with CE. Reconstruction with positive margins after initial excision was significantly more likely after CE (20.22%) versus MMS (0%) [p<0.001]. Compared to MMS, CE had higher rates of repeat excisions (20.22% vs. 1.67%) [p<0.001] and longer mean time to definitive reconstruction (11.35 vs. 1.44 days) [p<0.001].

Limitations: Single site, retrospective design.

Conclusion: Compared to MMS, CE of HFMs has higher rates of reconstruction with positive margins, repeat surgeries, and a longer time to definitive reconstruction.

{"title":"Mohs micrographic surgery reduces the risk of reconstruction with positive margins, repeat surgeries, and time to definitive reconstruction compared to conventional excision of hand and foot melanomas: a retrospective cohort study.","authors":"Daniela Frankel, Karla Valdes-Morales, Mara D Trifoi, Stephanie K Lin, Annika M Deitermann, Manisha Banala, Esther Zhang, Nicole Easo, Marissa Lubeck, Dylan Haynes, Daniel Lewis, Shannon T Nugent, Jeremy R Etzkorn, Neha N Jariwala, Junqian Zhang, Joanna L Walker, H William Higgins, Joseph F Sobanko, Cerrene N Giordano, Parnaz Daneshpajouhnejad, Mitul Modi, Ines C Lin, Benjamin Chang, Jason Wink, Giorgos Karakousis, John Miura, Christopher J Miller","doi":"10.1016/j.jaad.2025.03.012","DOIUrl":"https://doi.org/10.1016/j.jaad.2025.03.012","url":null,"abstract":"<p><strong>Background: </strong>Hand and foot melanomas (HFM) have increased risk for positive margins after conventional excision (CE). Mohs micrographic surgery (MMS) may improve margin clearance prior to reconstruction. Rates of reconstruction with positive margins have not been compared after CE versus MMS for HFM.</p><p><strong>Objective: </strong>To compare rates of reconstruction with positive margins after CE or MMS of HFM.</p><p><strong>Methods: </strong>In situ and invasive melanomas of hands and feet treated with CE or MMS with MART-1 immunostaining between 1994-2023 were identified from an academic center. The primary outcome was rate of reconstruction with positive margins after CE vs MMS. Secondary outcomes were repeat excision and time to definitive reconstruction after CE vs MMS.</p><p><strong>Results: </strong>Of 269 HFM, 180 (66.91%) were treated with MMS versus 89 (33.09%) with CE. Reconstruction with positive margins after initial excision was significantly more likely after CE (20.22%) versus MMS (0%) [p<0.001]. Compared to MMS, CE had higher rates of repeat excisions (20.22% vs. 1.67%) [p<0.001] and longer mean time to definitive reconstruction (11.35 vs. 1.44 days) [p<0.001].</p><p><strong>Limitations: </strong>Single site, retrospective design.</p><p><strong>Conclusion: </strong>Compared to MMS, CE of HFMs has higher rates of reconstruction with positive margins, repeat surgeries, and a longer time to definitive reconstruction.</p>","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":""},"PeriodicalIF":12.8,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143625031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Improved survival at the population level for patients with advanced Merkel cell carcinoma following availability of immunotherapy.
IF 12.8 1区 医学 Q1 DERMATOLOGY Pub Date : 2025-03-10 DOI: 10.1016/j.jaad.2025.03.006
Kelly G Paulson, Song Y Park, Shailender Bhatia, Daniel S Hippe, Paul Nghiem

Background: Merkel cell carcinoma (MCC) is an aggressive skin cancer with poor survival rates. Immune checkpoint inhibitors (ICIs) were FDA-approved for advanced MCC in 2017, but their real-world survival impact remains unclear.

Objective: Evaluate whether ICI introduction in the US corresponded with improved survival.

Methods: This cohort study analyzed SEER data for MCC patients diagnosed from 2010 to 2021, grouped by 3-year periods, to calculate 2-year overall and relative survival.

Results: For 453 patients with metastatic MCC, 2-year relative survival improved from 23% (2010-2012) to 37% (2013-2015), 42% (2016-2018), and 54% (2019-2021) (p < 0.001). Median overall survival also increased from 9 to 16 months among these patients. In 4,786 MCC patients overall, 2-year relative survival rose from 73% (2010-2012) to 81% (2019-2021) (p = 0.004), while overall survival improved from 67% to 72% (p = 0.012).

Limitations: SEER lacks case-level data to link ICI treatment directly to survival, although ICIs represent the major recent treatment advance for MCC.

Conclusions: The introduction of ICIs aligns with a >2-fold increase in survival for advanced MCC patients at the population level, translating to ∼220 fewer deaths per year in the U.S.

{"title":"Improved survival at the population level for patients with advanced Merkel cell carcinoma following availability of immunotherapy.","authors":"Kelly G Paulson, Song Y Park, Shailender Bhatia, Daniel S Hippe, Paul Nghiem","doi":"10.1016/j.jaad.2025.03.006","DOIUrl":"https://doi.org/10.1016/j.jaad.2025.03.006","url":null,"abstract":"<p><strong>Background: </strong>Merkel cell carcinoma (MCC) is an aggressive skin cancer with poor survival rates. Immune checkpoint inhibitors (ICIs) were FDA-approved for advanced MCC in 2017, but their real-world survival impact remains unclear.</p><p><strong>Objective: </strong>Evaluate whether ICI introduction in the US corresponded with improved survival.</p><p><strong>Methods: </strong>This cohort study analyzed SEER data for MCC patients diagnosed from 2010 to 2021, grouped by 3-year periods, to calculate 2-year overall and relative survival.</p><p><strong>Results: </strong>For 453 patients with metastatic MCC, 2-year relative survival improved from 23% (2010-2012) to 37% (2013-2015), 42% (2016-2018), and 54% (2019-2021) (p < 0.001). Median overall survival also increased from 9 to 16 months among these patients. In 4,786 MCC patients overall, 2-year relative survival rose from 73% (2010-2012) to 81% (2019-2021) (p = 0.004), while overall survival improved from 67% to 72% (p = 0.012).</p><p><strong>Limitations: </strong>SEER lacks case-level data to link ICI treatment directly to survival, although ICIs represent the major recent treatment advance for MCC.</p><p><strong>Conclusions: </strong>The introduction of ICIs aligns with a >2-fold increase in survival for advanced MCC patients at the population level, translating to ∼220 fewer deaths per year in the U.S.</p>","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":""},"PeriodicalIF":12.8,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143615722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Characteristics and outcomes of dipeptidyl peptidase-4 inhibitor-associated pemphigus patients: A retrospective analysis of 66 cases.
IF 12.8 1区 医学 Q1 DERMATOLOGY Pub Date : 2025-03-10 DOI: 10.1016/j.jaad.2025.01.103
Gaurav N Pathak, Anushka Pande, Babar K Rao
{"title":"Characteristics and outcomes of dipeptidyl peptidase-4 inhibitor-associated pemphigus patients: A retrospective analysis of 66 cases.","authors":"Gaurav N Pathak, Anushka Pande, Babar K Rao","doi":"10.1016/j.jaad.2025.01.103","DOIUrl":"https://doi.org/10.1016/j.jaad.2025.01.103","url":null,"abstract":"","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":""},"PeriodicalIF":12.8,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143615719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Disease severity and pruritus treatment outcomes in prurigo nodularis: A systematic review of randomized-controlled trials.
IF 12.8 1区 医学 Q1 DERMATOLOGY Pub Date : 2025-03-10 DOI: 10.1016/j.jaad.2025.03.009
Ryan S Q Geng, Siddhartha Sood, Jihad Waked, Rayyan Mahmood, Khalad Maliyar, Muskaan Sachdeva, Abrahim Abduelmula, Jensen Yeung, Asfandyar Mufti
{"title":"Disease severity and pruritus treatment outcomes in prurigo nodularis: A systematic review of randomized-controlled trials.","authors":"Ryan S Q Geng, Siddhartha Sood, Jihad Waked, Rayyan Mahmood, Khalad Maliyar, Muskaan Sachdeva, Abrahim Abduelmula, Jensen Yeung, Asfandyar Mufti","doi":"10.1016/j.jaad.2025.03.009","DOIUrl":"https://doi.org/10.1016/j.jaad.2025.03.009","url":null,"abstract":"","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":""},"PeriodicalIF":12.8,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143615721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Discount pharmacies may save patients significant money on androgenetic alopecia medications compared to both traditional pharmacies and direct-to-consumer companies.
IF 12.8 1区 医学 Q1 DERMATOLOGY Pub Date : 2025-03-10 DOI: 10.1016/j.jaad.2025.02.089
Manas Ranpariya, Jules B Lipoff
{"title":"Discount pharmacies may save patients significant money on androgenetic alopecia medications compared to both traditional pharmacies and direct-to-consumer companies.","authors":"Manas Ranpariya, Jules B Lipoff","doi":"10.1016/j.jaad.2025.02.089","DOIUrl":"https://doi.org/10.1016/j.jaad.2025.02.089","url":null,"abstract":"","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":""},"PeriodicalIF":12.8,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143615720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In-transit melanoma metastases: Evaluation and Management for the Dermatologist.
IF 12.8 1区 医学 Q1 DERMATOLOGY Pub Date : 2025-03-10 DOI: 10.1016/j.jaad.2025.03.005
Anagha Bangalore Kumar, James W Jakub, Scott C Lester, Svetomir N Markovic, Christian L Baum

In-transit metastases (ITM) are estimated to occur in 5-10% of primary cutaneous melanomas. They are classified as stage III disease in the American Joint Committee on Cancer classification system and are associated with approximately a 30% 10-year survival rate. The management of ITM is not standardized. Treatment options depend on the number of lesions, location, distribution of ITM and general medical condition of the patient. Topical, local, regional, and systemic treatment options can be considered for treatment. Dermatologists may play a unique role in management through skin-directed therapies.

{"title":"In-transit melanoma metastases: Evaluation and Management for the Dermatologist.","authors":"Anagha Bangalore Kumar, James W Jakub, Scott C Lester, Svetomir N Markovic, Christian L Baum","doi":"10.1016/j.jaad.2025.03.005","DOIUrl":"https://doi.org/10.1016/j.jaad.2025.03.005","url":null,"abstract":"<p><p>In-transit metastases (ITM) are estimated to occur in 5-10% of primary cutaneous melanomas. They are classified as stage III disease in the American Joint Committee on Cancer classification system and are associated with approximately a 30% 10-year survival rate. The management of ITM is not standardized. Treatment options depend on the number of lesions, location, distribution of ITM and general medical condition of the patient. Topical, local, regional, and systemic treatment options can be considered for treatment. Dermatologists may play a unique role in management through skin-directed therapies.</p>","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":""},"PeriodicalIF":12.8,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143615723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of the American Academy of Dermatology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1